title: Prevalence and Risk Factors Associated with Adverse Drug Reactions among Previously Treated Tuberculosis Patients in China.
abstract: We assessed the incidence of adverse drug reactions (ADRs) with anti-TB medications and evaluated the risk factors for developing ADRs in previously treated tuberculosis patients in China. All patients received the first-line anti-TB regimen (2HREZS/6HRE) as recommended by the national guidelines. Clinical and laboratory evaluations were performed once a month. Out of the 354 participants, 262 (74.0%) experienced ADRs such as hyperuricemia (65.0%, 230/354), hepatotoxicity (6.2%, 22/354) and hearing disturbances (4.8%, 17/354). ADRs were significantly associated with diabetes mellitus [OR (95% CI): 15.5 (2.07-115.87)]; however, weight more than 50 kg [OR (95% CI): 0.41 (0.22-0.85)] was a protective factor for occurrence of ADRs. Hyperuricemia is the most common adverse event but, most patients with hyperuricemia showed increased tolerance for high uric acid levels. Low body weight and diabetes mellitus increased the risk of the occurrence of ADRs during anti-TB treatment.
authors.affiliation: Beijing Tuberculosis & Thoracic Tumor Research Institute, Beijing 101149, China; Beijing Chest Hospital, Capital Medical University, Beijing 101149, China; Clinical Center on Tuberculosis, China CDC, Beijing 101149, China.
authors.forename: Xi Qin
authors.initials: XQ
authors.lastname: Han
authors.affiliation: Beijing Tuberculosis & Thoracic Tumor Research Institute, Beijing 101149, China; Beijing Chest Hospital, Capital Medical University, Beijing 101149, China; Clinical Center on Tuberculosis, China CDC, Beijing 101149, China.
authors.forename: Yu
authors.initials: Y
authors.lastname: Pang
authors.affiliation: Beijing Tuberculosis & Thoracic Tumor Research Institute, Beijing 101149, China; Beijing Chest Hospital, Capital Medical University, Beijing 101149, China; Clinical Center on Tuberculosis, China CDC, Beijing 101149, China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Ma
authors.affiliation: Beijing Tuberculosis & Thoracic Tumor Research Institute, Beijing 101149, China; Beijing Chest Hospital, Capital Medical University, Beijing 101149, China; Clinical Center on Tuberculosis, China CDC, Beijing 101149, China.
authors.forename: Yu Hong
authors.initials: YH
authors.lastname: Liu
authors.affiliation: Beijing Tuberculosis & Thoracic Tumor Research Institute, Beijing 101149, China; Beijing Chest Hospital, Capital Medical University, Beijing 101149, China; Clinical Center on Tuberculosis, China CDC, Beijing 101149, China.
authors.forename: Ru
authors.initials: R
authors.lastname: Guo
authors.affiliation: Beijing Tuberculosis & Thoracic Tumor Research Institute, Beijing 101149, China; Beijing Chest Hospital, Capital Medical University, Beijing 101149, China; Clinical Center on Tuberculosis, China CDC, Beijing 101149, China.
authors.forename: Wei
authors.initials: W
authors.lastname: Shu
authors.affiliation: Beijing Tuberculosis & Thoracic Tumor Research Institute, Beijing 101149, China; Beijing Chest Hospital, Capital Medical University, Beijing 101149, China; Clinical Center on Tuberculosis, China CDC, Beijing 101149, China.
authors.forename: Xue Rui
authors.initials: XR
authors.lastname: Huang
authors.affiliation: Beijing Tuberculosis & Thoracic Tumor Research Institute, Beijing 101149, China; Beijing Chest Hospital, Capital Medical University, Beijing 101149, China; Clinical Center on Tuberculosis, China CDC, Beijing 101149, China.
authors.forename: Qi Ping
authors.initials: QP
authors.lastname: Ge
authors.affiliation: Beijing Tuberculosis & Thoracic Tumor Research Institute, Beijing 101149, China; Beijing Chest Hospital, Capital Medical University, Beijing 101149, China; Clinical Center on Tuberculosis, China CDC, Beijing 101149, China.
authors.forename: Jian
authors.initials: J
authors.lastname: DU
authors.affiliation: Beijing Tuberculosis & Thoracic Tumor Research Institute, Beijing 101149, China; Beijing Chest Hospital, Capital Medical University, Beijing 101149, China; Clinical Center on Tuberculosis, China CDC, Beijing 101149, China.
authors.forename: Wei Wei
authors.initials: WW
authors.lastname: Gao
mesh_terms: D000293:Adolescent; D000328:Adult; D000995:Antitubercular Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D003920:Diabetes Mellitus; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D012189:Retrospective Studies; D012307:Risk Factors; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy* / Q000453:epidemiology; D055815:Young Adult
chemical_list: D000995:Antitubercular Agents
keywords: Adverse drug reactions; Anti-TB medications; Tuberculosis; Tuberculosis treatment